ClinicalTrials.gg
Active, not recruitingNCT06268873Updated Jun 26, 2026

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

A Phase 3 interventional study of Baxdrostat/dapagliflozin and Dapagliflozin in combination with placebo in Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca. Active, not recruiting at 565 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,554
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.

Enrollment
5th of 40
2,554 · median 100
Started
2024
with 5 others
Phase 3
10 of 40
5 open now
Primary completion
2028-02
later than 15 of 20 live
Registered
20th of 40
by date
Lead sponsor
9 of 40
AstraZeneca

Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 5th largest by enrollment, is one of 6 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 15 of the 20 other live ones, and was the 20th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN.

This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or placebo/dapagliflozin; and approximately 12-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 12-weeks (approximately), where reassessment of eGFR will occur for the primary efficacy endpoint.

In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.

03

Conditions studied

  • Chronic Kidney Disease and Hypertension

Keywords

  • Chronic kidney disease
  • Hypertension
  • Blood pressure
  • Baxdrostat
  • Dapagliflozin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants of any sex and gender must be ≥ 18 years old, or older, at the time of signing the .
  2. Participants with CKD and ≥ 30 and \< 90 mL/min/1.73 m2 at screening
  3. Urine albumin creatinine ratio > 200 mg/g (22.6 mg/mmol) and \< 5000 mg/g (565 mg/mmol) at screening
  4. Participants with history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the randomisation visit
  5. Stable and maximum tolerated dose of an ACE inhibitor or an ARB (not both) for at least 4 weeks prior to Screening Visit
  6. Central laboratory serum potassium must meet the following criteria at the Screening Visit, based on screening eGFR:

    • for participants with screening eGFR ≥ 45 mL/min/1.73 m2, potassium must be ≥ 3.0 and ≤ 4.8 mmol/L at the Screening Visit
    • for participants with screening eGFR \< 45 mL/min/1.73 m2, potassium must be ≥ 3.0 and ≤ 4.5 mmol/L at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure > 180 mmHg, or DBP > 110 mmHg at screening.
  2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months at screening.
  3. Serum sodium \< 135 mmol/L at the Screening Visit, determined as per central laboratory.
  4. Diabetes mellitus:

    (a) T1DM at Screening Visit: (i) For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion.

    (ii) For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion.

    (b) Uncontrolled T2DM at screening: > 10.5% (> 91 mmol/mol).

  5. functional HF class IV at screening.
  6. Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation.
  7. Any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit.
  8. Any acute kidney injury within 3 months prior to the Screening Visit
  9. History of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant).
  10. History or ongoing allergy/, as judged by the investigator, to SGLT2 inhibitor (eg, empagliflozin) or ASI.
  11. Any clinical condition requiring systemic therapy other than stable maintenance therapy for at least 3 months prior to Visit 1.
  12. Any use of mineralocorticoid receptor antagonists (such as spironolactone, eplerenone, or finerenone), potassium-sparing diuretics (such as triamterene or amiloride), or potassium binders (such as sodium zirconium cyclosilicate, patiromer, or sodium polystyrene sulfonate) within 4 weeks prior to screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,554 participants (actual)

Study arms

  • Experimental
    Baxdrostat/dapagliflozin

    Participants randomised to the baxdrostat/dapagliflozin arm will initially receive a dose of baxdrostat lower dose and dapagliflozin. For participants that meet the up-titration criteria, baxdrostat may be up-titrated to higher dose.

    Drug: Baxdrostat/dapagliflozin

  • Active comparator
    Dapagliflozin

    Patients will receive one dose of dapagliflozin (active comparator) in combination with placebo matching baxdrostat daily

    Drug: Dapagliflozin in combination with placebo

Interventions

  • DrugBaxdrostat/dapagliflozin

    Drug pages: Baxdrostat · Dapagliflozin

    baxdrostat tablet dapagliflozin tablet

    Also known as: Baxdrostat CIN-107

  • DrugDapagliflozin in combination with placebo

    dapagliflozin tablet placebo tablet

06

What researchers measure

Primary outcomes

  1. To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR over time.

    Change from baseline in eGFR to post treatment.

    Time frame: Baseline - 2 years + 12 weeks

Secondary outcomes

  1. To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone at reducing UACR (urine albumin-creatinine ratio).

    Change from baseline in UACR

    Time frame: Baseline -16 weeks

  2. To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone at reducing SBP.

    Change from baseline in systolic BP (blood pressure).

    Time frame: Baseline -16 weeks

  3. To determine whether baxdrostat/dapagliflozin compared with dapagliflozin alone slows CKD progression and reduces the risk of ESKD (End-stage kidney disease).

    Kidney hierarchical composite endpoint.\* \*Defined as the most severe outcome of the following: 1. Death; 2. KFRT (chronic dialysis or kidney transplant); 3. Sustained GFR \< 15 mL/min/1.73 m2; 4. Sustained GFR decline from baseline of ≥ 57%; 5 Sustained GFR decline from baseline of ≥ 50%; or 6. individual change from baseline to post-treatment eGFR if none of the outcomes occurred.

    Time frame: baseline - 2 years + 12 weeks

  4. To determine whether baxdrostat/dapagliflozin compared with dapagliflozin alone slows the rate of kidney function decline after the hemodynamically-mediated acute effect on GFR (Glomerular Filtration Rate).

    Change in eGFR from following randomisation.

    Time frame: 8 weeks following randomisation to end of treatment

  5. To determine whether baxdrostat/dapagliflozin is superior to dapagliflozin alone in reducing the risk of MACE

    Time to the first occurrence of any of the components of the composite of: 1. CV death 2. HF with and without hospitalization 3. MI 4. Stroke

    Time frame: Baseline - 24 months

Other outcomes

  1. Adverse Events - Number of participants with Adverse Events

    Time frame: Baseline - 24 months

  2. Clinical Laboratory - Number of participants with Abnormal clinical laboratory measurements

    Time frame: Baseline - 24 months

  3. Vital Signs - Number of participants with Abnormal vital signs

    Time frame: Baseline - 24 months

  4. Electrocardiogram- Number of Participants With Abnormal ECG

    Time frame: Baseline - 24 months

07

Study locations

565 sites
  • Research Site
    Fairhope, Alabama 36532, United States
  • Research Site
    Phoenix, Arizona 85016, United States
  • Research Site
    Surprise, Arizona 85374, United States
  • Research Site
    Tucson, Arizona 85710, United States
  • Research Site
    Searcy, Arkansas 72143, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Canyon Country, California 91351, United States
  • Research Site
    Fremont, California 94538, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    San Francisco, California 94110, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Denver, Colorado 80220, United States
  • Research Site
    New Britain, Connecticut 06051, United States
  • Research Site
    Boca Raton, Florida 33487, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Edgewater, Florida 32132, United States
  • Research Site
    Fort Lauderdale, Florida 33316, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Jacksonville Beach, Florida 32250, United States
  • Research Site
    Lake City, Florida 32055, United States
  • Research Site
    Lake Worth, Florida 33467, United States
  • Research Site
    Melbourne, Florida 32901, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    New Port Richey, Florida 34652, United States
  • Research Site
    Ocoee, Florida 34761, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Orlando, Florida 32808, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    Riverview, Florida 33578, United States
  • Research Site
    Winter Haven, Florida 33880, United States
  • Research Site
    Atlanta, Georgia 30344, United States
  • Research Site
    Conyers, Georgia 30094, United States
  • Research Site
    Macon, Georgia 31210, United States
  • Research Site
    Champaign, Illinois 61822, United States
  • Research Site
    Hazel Crest, Illinois 60429, United States
  • Research Site
    Huntley, Illinois 60142, United States
  • Research Site
    Rockford, Illinois 61107, United States
  • Research Site
    Evansville, Indiana 47714, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Hutchinson, Kansas 67502, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Bethesda, Maryland 20889, United States
  • Research Site
    Lanham, Maryland 20706, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    New Bedford, Massachusetts 02740, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Pontiac, Michigan 48341, United States
  • Research Site
    Saint Joseph, Michigan 49085, United States
  • Research Site
    City of Saint Peters, Missouri 63376, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Kansas City, Missouri 64128, United States
  • Research Site
    Kansas City, Missouri 64151, United States
  • Research Site
    St Louis, Missouri 63136, United States
  • Research Site
    Eatontown, New Jersey 07724, United States
  • Research Site
    Binghamton, New York 13905, United States
  • Research Site
    Manhasset, New York 11030, United States
  • Research Site
    Middletown, New York 10940, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Niagara Falls, New York 14304, United States
  • Research Site
    Orchard Park, New York 14127, United States
  • Research Site
    Rockville Centre, New York 11570, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Statesville, North Carolina 28625, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Wilmington, North Carolina 28412, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Chester, Pennsylvania 19013, United States
  • Research Site
    Langhorne, Pennsylvania 19047, United States
  • Research Site
    Uniontown, Pennsylvania 15401, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    East Providence, Rhode Island 02915, United States
  • Research Site
    Providence, Rhode Island 02904, United States
  • Research Site
    Charleston, South Carolina 29414, United States
  • Research Site
    Columbia, South Carolina 29203, United States
  • Research Site
    Sioux Falls, South Dakota 57104, United States
  • Research Site
    Chattanooga, Tennessee 37421, United States
  • Research Site
    Memphis, Tennessee 38105, United States
  • Research Site
    Memphis, Tennessee 38115, United States
  • Research Site
    Arlington, Texas 76015, United States
  • Research Site
    Austin, Texas 78726, United States
  • Research Site
    Austin, Texas 78751, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77040, United States
  • Research Site
    Houston, Texas 77084, United States
  • Research Site
    Houston, Texas 77099, United States

Showing the first 100 of 565 sites across 38 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Muhammad Daniyal S, Ajaz H, Riaz M, Murad Khatoon N, Aftab Z, Tauqir Gondal H, Gul I, Sarwar M, Batool F, Fahim SL, Noor A, Khalid A, Ashraf DA, Jabarkhil R. Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in chronic kidney disease: an updated meta-analysis of randomized controlled trials. BMC Nephrol. 2025 Dec 22;27(1):69. doi: 10.1186/s12882-025-04710-2. PubMed 41430169 ↗
  • Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026 Feb 1;37(2):299-311. doi: 10.1681/ASN.0000000849. Epub 2025 Sep 6. PubMed 40913594 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2028, 46 months after the start.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 46 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 20, 2024
StartActual
Mar 29, 2024
Primary completionEst.
Feb 24, 2028
CompletionEst.
Feb 24, 2028
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06268873
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Mar 29, 2024
Primary completion
Feb 24, 2028 (estimated)
Completion
Feb 24, 2028 (estimated)
Last update
Jun 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Baxdrostat · Dapagliflozin

Start the discussion